Corticosteroids for COVID-19
(STAR Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the effectiveness of corticosteroids, a medication that reduces inflammation, for adults hospitalized with severe respiratory infections and low oxygen levels. Participants will receive either a corticosteroid treatment or no additional treatment to determine if the medication improves their condition. The trial seeks individuals hospitalized with severe breathing problems and low oxygen levels, excluding those with known COVID-19 or conditions that corticosteroids could worsen. As a Phase 4 trial, this research aims to understand how the already FDA-approved and effective treatment benefits more patients.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are on high doses of corticosteroids, you may not be eligible to participate.
What is the safety track record for this treatment?
Research has shown that corticosteroids can help people with COVID-19 by reducing the risk of death and slowing disease progression. Studies have examined both high and low doses of these drugs. Although results vary, they generally appear safe for short-term use.
One study found that corticosteroids reduced the need for intensive care and breathing machines, indicating that patients usually tolerate them well. However, the optimal treatment duration appears to be about six days, which this trial is testing.
These findings suggest that corticosteroids are generally safe for people with severe COVID-19. However, every treatment carries risks, so it is important to consider both the benefits and possible side effects.12345Why are researchers enthusiastic about this study treatment?
Researchers are excited about using corticosteroids for COVID-19 because they may offer rapid relief by reducing inflammation in severely ill patients. Unlike typical antiviral treatments that target the virus itself, corticosteroids work by calming the immune system's aggressive response, which can be more harmful than the virus in severe cases. This approach could potentially lead to quicker recovery times and shorter hospital stays for patients.
What is the effectiveness track record for corticosteroids in treating severe acute respiratory infections?
Research has shown that corticosteroids can reduce the risk of death in patients with severe COVID-19. Studies have found that these medications can lower the death rate by about 20% in such cases. In this trial, participants in the corticosteroid group will receive systemic corticosteroids, the first drugs identified to decrease the risk of death in critically ill COVID-19 patients. Experts agree that these medications effectively manage severe breathing problems, including those caused by COVID-19. Research from China and other countries supports this view.24678
Who Is on the Research Team?
Cavan Reilly, PhD
Principal Investigator
University of Minnesota
Are You a Good Fit for This Trial?
The STAR Trial is for adults hospitalized with severe acute respiratory infections and low oxygen levels, likely due to COVID-19. Participants must not have other health conditions that could interfere with the study or be on treatments that affect immune response.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive systemic corticosteroids at a dose equivalent to 40 mg of prednisolone per day for 7 days or until discharge
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Corticosteroid
Trial Overview
This trial tests if a steroid treatment (equivalent to 40 mg of prednisolone per day) for 7 days can help patients compared to no steroid use. It's conducted across multiple centers where patients are randomly assigned to one of the two groups.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Participants in the corticosteroid group will receive systemic corticosteroids at a dose equivalent to 40 mg of prednisolone per day for 7 days or until discharge, whichever is sooner. Clinicians will select the systemic corticosteroid medication and the route of administration.
Participants in the no corticosteroid group will not receive systemic corticosteroids for 7 days or until hospital discharge, whichever is sooner, unless (i) they meet prespecified criteria for the administration of systemic corticosteroids (e.g., anaphylaxis) or (ii) their clinicians determine that the administration of systemic corticosteroids is required for the optimal care of the participant for other reasons.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Minnesota
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
Citations
Effectiveness of corticosteroids to treat coronavirus disease ...
Our results showed that corticosteroid therapy was related to a reduction in all-cause mortality in severe COVID-19 patients.
Efficacy of corticosteroids in COVID-19: An evidence-based ...
Historically, corticosteroids have shown efficacy in treating other severe respiratory conditions, such as Middle East Respiratory Syndrome (MERS),7 Acute ...
Efficacy of different doses of corticosteroids in treating severe ...
Systemic corticosteroids are considered effective in treating severe or critical COVID-19 patients in both Chinese and international consensus ...
Corticosteroids for hospitalized patients with severe/critical ...
Corticosteroids were identified as the first drug able to reduce mortality in severe or critically ill patients with COVID-19.
Coronavirus disease (COVID-19): Corticosteroids, ...
Data from these studies show that deaths are reduced by 20% when patients with severe COVID-19 are given corticosteroid treatment during their ...
Corticosteroid use in COVID-19 patients: a systematic ...
Our findings from both observational studies and RCTs confirm a beneficial effect of corticosteroids on short-term mortality and a reduction in need for ...
Systemic Corticosteroids for COVID-19
It was the first trial to suggest that systemic corticosteroids, such as dexamethasone, may decrease the risk of death and decrease the progression of disease ...
Optimal Duration of Systemic Corticosteroids in Coronavirus ...
In this meta-analysis, optimal duration of corticosteroids for hospitalized COVID-19 patients was up to 6 days, with no additional survival benefit with &g.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.